.

Department of Pathology, Microbiology, and Immunology

 
 Samir L. Aleryani, PhD, MT (ASCP), CLS (NCA)
 
 
Assistant Professor
Dept. of Pathology, Microbiology and Immunology
Medical Director, Laboratory Support Services
 
  
 Contact Information
 
 
Office Location:
TVC 4603B
Phone: 615-322-1178
 
Campus Mail address:
Pathology Labs/Blood Banks
TVC 4605 (5310)
 
US Mailing Address:
Medical Director, Laboratory Support Services
Pathology Labs/Blood Banks
TVC 4605
1301 Medical Center Drive
Nashville, TN 37232-5310
-----------------------------------------------------------
Please click here for Vanderbilt Pathology Services
 
  
 Research Key Words
 
 
Cystic Fibrosis, Nirtric Oxide (NO), Reactive Oxygen Species (ROS), Antioxidants, Nitrosothiols (RNSOs), Fatty, Fatty Acids (FAs), Pyroxinitrite (ONOO-), Glutathione (GSH), nitrosoglutathione (GSNO), Ceremide, Phospholipids, Catalase.
 
  
 Research Specialty
 
 
Nitric Oxide Chemistry, fatty acids and Cystic fibrosis abnormality
 
  
 Research Description
 
 
My research is focused in the study of pathogenesis of the cystic fibrosis (CF).   CF is the most common inherited disorder affecting Caucasians in the United States. CF is caused by mutations in the cystic fibrosis transmembrane regulator (CFTR). These mutations cause a multitude of pulmonary, gastrointestinal, and endocrine defects leading to significant morbidity and early mortality. These mutations cause a multitude of pulmonary, gastrointestinal, and endocrine defects leading to significant morbidity and early mortality. Individuals with cystic fibrosis (CF) exhibit consistent alterations in polyunsaturated fatty aicd (PUFA) levels, including decreased linoleate (LA; 18:2n-6) and docosahexaenoate (DHA; 22:6n-3), and variably increased arachidonate (AA; 20:4n-6). In addition, CF patients show abnormalities in levels of the sphingolipid, ceramide, and “free radical resistance” at the cellular level.
 
The search for drug therapy for the treatment of CF is an important area where my research is focused. We have shown that Fenretinide, an anti-tumor drug, can correct some of the fatty acids abnormalities. Other potential drugs are being investigated.
 
  
 Publications
 
 
 
 
 
 
 
 
 
 
Aleryani SL, Waddah Katrangi , Adam C. Seegmiller, Michael Laposata. Fenretinide (4-HPR) Corrects the Commonly Altered Fatty Acid Concentrations in Cultured Bronchial Epithelial Cells with Absent CFTR. Submitted to the Cystic Fibrosis Foundation. Accepted.